Board of Directors

The Board of Directors manages the company on behalf of the Shareholders.

Michael Shalmi

Chairman of the Board

Chairman since 2019.

Born: 1965.

Education: Physician from University of Copenhagen and obtained his MBA following studies at Scandinavian International Management Institute in Copenhagen.

Shareholding in the Company: 336,718 shares.

Other assignments:

  • CEO and owner of Aligned Clinical Management Services. CEO at P/S Momentum Energy Jutlandia, K/S Momentum Energy Jutlandia Development and K/S Momentum Energy Hanstholm
  • Chairman of the Board of Momentum Gruppen A/S and Curexsys AG

Previous assignments (last five years):

  • Board member of Evotec AG
  • Managing Director and Head of Principal Investments of Novo Holdings A/S

Aleksandar Danilovski

Board Member

Board member since 2020.

Born: 1974.

Education: Ph.D. in Chemistry from Cambridge University and University of Zagreb.

Shareholding in the Company: 106,688 shares.

Other assignments:

  • Chief Scientific Officer (CSO) at Xellia Pharmaceuticals
  • Board member of Pharmaero ApS
  • Member of the Scientific Selection Board of Novo Holdings – REPAIR Impact Fund

Previous assignments:

  • Head of European R&D for Barr Laboratories, Inc.
  • Member of Management Board of PLIVA Pharmaceuticals

Axel Glasmacher

Board Member

Board member since 2020.

Born: 1960.

Education: Doctor of Medicine, since 2009 an adjunct professor of medicine at the University of Bonn, Germany.

Shareholding in the Company: 40,000 shares.

Other assignments:

  • Member of the Clinical Advisory Board of Oncopeptides AB
  • Member of the Board of Cancer DrugDevelopment Forum
  • Non-Executive Chairperson of the Board of Directors to 4D pharma plc
  • Member of the Supervisory Board of  Ryvu S.A.
  • Member of the Board of Directors of AvenCell Therapeutics Inc.

Previous assignments:

  • Head of Global Clinical R&D and Senior Vice President for Celgene

Uli Hacksell

Board Member

Board member since 2019.

Born: 1950.

Education: Master of Pharmacy, PhD in Medicinal Chemistry, Professor in Organic Chemistry.

Shareholding in the Company: 21,000 shares.

Other assignments:

  • Chairman of Medivir AB and Annexin Pharmaceuticals AB
  • Boardmember of Index Pharmaceuticals Holding AB and Synact Pharma AB

Previous assignments (last five years):

  • CEO of ACADIA Pharmaceuticals
  • CEO and Chairman of the Board of Cerecor

Elaine Sullivan

Board Member

Board member since 2020.

Born: 1961.

Education: Ph.D. in Molecular Virology from the University of Edinburgh.

Shareholding in the Company: None.

Other assignments:

  • CEO and Co-Founder of Curadh Pharmaceuticals
  • Non-Executive Director of the IP Group plc and Open Orphan
  • Member of the Supervisory Board of Evotec AG

Previous assignments:

  • Vice President Global External Research & Development at Lilly
  • Vice President R&D; Head of New Opportunities Therapy Area and Vice President, Science & Technology at Astra Zeneca
  • CEO and Co-Founder of Carrick Therapeutics

Peter Thelin

Board Member

Board member since 2011.

Born: 1956.

Education: Graduate of Stockholm School of Economics.

Shareholding in the Company: 4,715,220 shares (privately and through companies).

Other assignments:

  • Board member and Partner of Brummer & Partners AB, ELC Fastigheter AB, East Bay AB, Sjunda Gård AB, Carve Intressenter AB, Sjuenda Holding AB and Rebellion Oil AB
  • Chairman in Stiftelsen Hjärnfonden

Previous assignments (last five years):

  • CEO of Carve Capital AB
  • Chairman of the board of directors of Jemtia AB, SRE Högfors AB and Acrux Entreprenad AB
  • Board member of CPB Energy AB, Valot Invest Sweden AB, Henvålens Fjällgård AB, Psoriasis + Creams Sweden AB and Järna Mejeri AB